{
    "nctId": "NCT00096369",
    "briefTitle": "Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer",
    "officialTitle": "An Exploratory Study to Identify Potential Surrogate Endpoint Biomarkers That Are Modulated by Tamoxifen vs. Placebo in Women With an Increased Risk for Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 130,
    "primaryOutcomeMeasure": "Plasma levels of hormones and binding proteins as measured by ELISA, IHC, and TUNEL at baseline and 3 months",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* At increased risk for breast cancer, as defined by 1 of the following criteria:\n\n  * Histologically confirmed lobular carcinoma in situ (LCIS) treated by local excision only\n  * Composite increased breast cancer risk of \u2265 1.67% over 5 years, based on the following criteria:\n\n    * Age\n    * Number of first-degree female relatives with breast cancer\n    * One or more prior breast biopsies\n\n      * Fine-needle aspiration cytology of a non-cystic lesion in lieu of an open biopsy is considered a biopsy\n    * Prior diagnosis of atypical hyperplasia of the breast\n    * Age at first live birth\n    * Nulliparity\n    * Race\n    * Age at onset of menarche\n* No prior or suspected invasive breast cancer or ductal carcinoma in situ\n* No clinical evidence of malignancy by physical examination, including a breast examination within the past 3 months\n* No evidence of suspicious or malignant disease or uncharacterized lesions on bilateral mammogram within the past 6 months\n* Normal gynecologic examination, including a bimanual pelvic examination and, if indicated, pap smear within the past 12 months\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 35 and over\n\nSex\n\n* Female\n\nMenopausal status\n\n* Premenopausal and ovulating\\*, defined as having regular menses for the past 6 months OR irregular menses with follicular phase (i.e., day 3) follicle-stimulating hormone level \\< 20 mIU/mL OR\n* Postmenopausal NOTE: \\* Ovulation is determined by day 21 progesterone level \\> 3 ng/mL\n\nPerformance status\n\n* ECOG 0-2\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Complete blood count normal\n* No active bleeding disorder (e.g., qualitative or quantitative platelet abnormality, hemophilia, or von Willebrand's disease)\n\nHepatic\n\n* Liver function tests normal\n\nRenal\n\n* Not specified\n\nCardiovascular\n\n* No prior deep-vein thrombosis except a single occurrence related to lower extremity trauma\n* No prior cerebral vascular accident\n* No prior transient ischemic attack\n\nPulmonary\n\n* No prior pulmonary embolus except a single occurrence related to lower extremity trauma\n\nOther\n\n* No saline or silicone breast implants\n* No known allergy to tamoxifen\n* No macular degeneration\n* No malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n* No nonmalignant disease that would preclude administration of tamoxifen\n* No psychiatric condition, including a history of clinical depression or addictive disorder, that would preclude giving informed consent or study compliance\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective nonhormonal contraception during and for 3 months after study participation\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* No prior systemic adjuvant chemotherapy for LCIS\n\nEndocrine therapy\n\n* No prior tamoxifen, raloxifene, or other selective estrogen-receptor modulators\n* At least 3 months since prior and no concurrent use of any of the following drugs:\n\n  * Estrogen or progesterone replacement therapy\n  * Oral contraceptives\n  * Androgens\n  * Luteinizing hormone-releasing hormone analogs\n  * Prolactin inhibitors\n  * Antiandrogens\n  * Steroids\n* No concurrent steroids for asthma\n\nRadiotherapy\n\n* No prior radiotherapy for LCIS\n\nSurgery\n\n* No prior bilateral prophylactic mastectomy\n* No prior mastectomy for LCIS\n\nOther\n\n* Concurrent nonhormonal medications allowed\n* No concurrent warfarin or cholestyramine\n* No prior or concurrent participation in any other cancer prevention study\n\n  * Patients treated with placebo on protocol NSABP-P-1 are eligible",
    "sex": "FEMALE",
    "minimumAge": "35 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}